If you, a family member, or loved one have taken the medication
Pradaxa and suffered from uncontrolled and/or excessive bleeding, heart attack,
or experienced other serious or fatal side effects, you might be entitled
Pradaxa (dabigatran) is a blood-thinning medicine approved by the U.S. Federal
Drug Administration (FDA) in October 2010 and manufactured by Boehringer
Ingelheim Pharmaceuticals Inc. The drug is marketed for stroke prevention
atrial fibrillation. People who have
atrial fibrillation have occasional "fluttering" in the heart, which increases the
risk that blood will pool in the heart, form a clot, and be pumped into
the brain (causing stroke).
Pradaxa reduces the risk of strokes by inhibiting
thrombin, an enzyme that is necessary for the formation of blood clots.
Pradaxa was developed as an alternative to Warfarin and is widely prescribed for
off label use as a "new generation" of anti-coagulant medication.
However, Warfarin is inactivated by many foods containing Vitamin K and
in an emergency, doctors can administer a simple dose of Vitamin K, which
allows blood to clot and prevents bleeding to death.
In contrast, when a
Pradaxa patient needs emergency treatment, they must undergo dialysis to mechanically remove
Pradaxa from the bloodstream. This can take several hours. By the time dialysis
takes effect, a person can bleed to death — even from a minor injury.
As a result, the FDA is evaluating reports of serious or even fatal bleeding
events in patients taking
Pradaxa. In 2011, manufacturer Boehringer Ingelheim admitted to knowledge of cases
of fatal bleeding yet they continue to market the drug.
Pradaxa warns of side effects of bleeding which can lead to death, as well as:
- Blood in urine
- Red/black tarry stool
- Unusual bruising
- Brain bleed
- Stroke or Heart Attack